

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 6/5/1966
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

C5 Inhibitors Drug Monitoring Panel

ARUP test code 3005961

Complement C5, Concentration

4 mg/dL L (Ref Interval: 7-20)

Low C5 concentration suggests inherited or acquired C5 deficiencies, or a secondary consumption process due to the liver incapable of keeping up with the synthesis of complement proteins. Low C5 concentration accompanied with low C3 (test code 0050150) and C4 (test code 0050155) concentrations indicate secondary consumption of complements. Low C5 concentration accompanied with normal C3 and C4 concentrations indicate a C5 deficiency.

Alternative Complement Pathway Activity

28 % Normal L (Ref Interval: >=31)

Absent or low complement alternative pathway functional (AH50) activity indicates inherited or acquired deficiencies in complement components, or a secondary consumption process or response to therapy. Low or absent AH50 activity with normal total complement functional (CH50, test code 3002575) activity suggests defects in alternate complement pathway. Low CH50 and AH50 results suggest defects in late complement components C3-C9 or a secondary consumption of complements. Low or absent AH50 activity due to abnormal control of the complement alternative pathway may occur in kidney diseases such as atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease, as well as in atypical postinfectious glomerulonephritis. If low AH50 value is unexpected or does not correlate with the patient's clinical condition, repeat analysis with a fresh frozen serum specimen is suggested for verification.

Interpretive Information: Alternative Complement Pathway Activity

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Complement Activity, Total Turbidimetric

69.0 U/mL (Ref Interval: 38.7-89.9)

H=High, L=Low, *=Abnormal, C=Critical

Normal activity in total complement functional assay (CH50) suggests normal presence and function of complement components, C1-C9. However, normal CH50 result can also occur in the presence of low levels of complement components due to excess presence of complement proteins in human serum. If clinically indicated, measurement of individual complement components is recommended. Normal CH50 result with low complement alternate pathway functional (AH50, test code 2005373) activity suggests defects in the alternate pathway.

REFERENCE INTERVAL: Complement Activity Total, (CH50)

38.6 U/mL or lessLow
38.7-89.9 U/mLNormal
90.0 U/mL or greaterHigh

Complement C5, Functional

17.0 U/mL L (Ref Interval: >=23.0)

Low C5 functional activity suggests inherited or acquired C5 deficiencies or can indicate response to therapy. Low C5 functional activity accompanied with low C5 concentration (Test code: 0050156) and low C3 (Test code: 0050150) and C4 (Test code: 0050155) concentrations indicate secondary consumption of complements.

REFERENCE INTERVAL: Complement C5, Functional

Low: Less than 23 U/mL
Low-Normal: Greater than or equal to 23-28.3 U/mL
Normal: Greater than 28.3 U/mL

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

C5 Inhibitors Drug Monitoring Pan Interp

See Note

INTERPRETIVE INFORMATION: C5 Inhibitors Drug Monitoring Panel

Patients treated with C5 inhibitors may show decreased/absent activity in total complement functional assay (CH50), alternative pathway functional assay (AH50), and C5 functional assay with normal or elevated C5 protein concentrations. Normal CH50, AH50, or C5 functional activity with normal or elevated C5 protein concentrations indicate inadequate complement blockage. Serial measurements are recommended when monitoring treatment efficacy. Decreases in both C5 concentration and C5 functional activity suggests a secondary consumption process or C5 deficiency. Repeat testing using a new specimen is suggested if in vitro complement activation and consumption of components due to conditions of collection, transport, and/or handling is suspected.

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Complement C5, Concentration	23-234-117532	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Alternative Complement Pathway Activity	23-234-117532	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Complement Activity, Total Turbidimetric	23-234-117532	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Complement C5, Functional	23-234-117532	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
C5 Inhibitors Drug Monitoring Pan Interp	23-234-117532	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-234-117532
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 9/22/2023 11:10:40 AM
4848